Compare Gilead Sciences, Inc. (GILD) vs OneSpan Inc (OSPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs OneSpan Inc — how do they compare? Gilead Sciences, Inc. trades at $135.56 (market cap $163.51B), while OneSpan Inc trades at $15.6 (market cap $571.66M). The key difference: Gilead Sciences, Inc. is far larger — about 286× OneSpan Inc's market cap, and OneSpan Inc pays the higher dividend (3.37%). Which is the better fit depends on your goals.
| GILD | OSPN | |
|---|---|---|
Market Cap | $163.51B | $571.66M |
Sector | Health | Technology |
52-Week High | $155.80 | $16.32 |
52-Week Low | $108.22 | $10.15 |
Enterprise Value | $178.05B | $529.87M |
Dividend Yield | 2.49% | 3.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
OSPN trades at $15.70, up 1.36% today, with a bullish technical signal from moving averages and strong profitability metrics including a 28.47% net income margin and 27.81% ROE. Recent earnings beats and a scheduled Q2 2026 report on August 4, 2026, highlight operational momentum, while a dividend payment in June 2026 adds shareholder return.
The stock presents a value opportunity with a P/E of 8.52, supported by analyst consensus of Buy (66.7%) and a $13.50 price target. Risks include negative net cash flow trends and competitive pressures in cybersecurity, but earnings consistency and institutional optimism suggest upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →
